DrugCite
Search

VAGISTAT

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Vagistat Adverse Events Reported to the FDA Over Time

How are Vagistat adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Vagistat, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Vagistat is flagged as the suspect drug causing the adverse event.

Most Common Vagistat Adverse Events Reported to the FDA

What are the most common Vagistat adverse events reported to the FDA?

Drug Ineffective
177 (11.2%)
Vaginal Swelling
139 (8.79%)
Drug Interaction
70 (4.43%)
Vulvovaginal Discomfort
62 (3.92%)
International Normalised Ratio Incr...
48 (3.04%)
Vaginal Haemorrhage
45 (2.85%)
Vaginal Discharge
43 (2.72%)
Abdominal Pain
27 (1.71%)
Dysuria
25 (1.58%)
Hypersensitivity
24 (1.52%)
Wrong Technique In Drug Usage Proce...
18 (1.14%)
Show More Show More
Maternal Drugs Affecting Foetus
17 (1.08%)
Off Label Use
17 (1.08%)
Foreign Body Trauma
16 (1.01%)
Thermal Burn
15 (.95%)
Blister
14 (.89%)
Localised Oedema
14 (.89%)
Nausea
14 (.89%)
Skin Haemorrhage
14 (.89%)
Vulvovaginal Burning Sensation
14 (.89%)
Erythema
13 (.82%)
Anaphylactoid Reaction
12 (.76%)
Dyspnoea
12 (.76%)
Headache
12 (.76%)
Haematuria
11 (.7%)
Muscle Spasms
11 (.7%)
Abortion Spontaneous
10 (.63%)
Dizziness
10 (.63%)
Pain
10 (.63%)
Vomiting
10 (.63%)
Accidental Exposure
9 (.57%)
Drug Administration Error
9 (.57%)
Incorrect Drug Administration Durat...
9 (.57%)
Product Quality Issue
9 (.57%)
Pruritus
9 (.57%)
Vulvovaginal Pruritus
9 (.57%)
Anaphylactic Reaction
8 (.51%)
Cervical Polyp
8 (.51%)
Contusion
8 (.51%)
Dermatitis
8 (.51%)
Gastrointestinal Haemorrhage
8 (.51%)
Intentional Drug Misuse
8 (.51%)
Oedema Genital
8 (.51%)
Pregnancy
8 (.51%)
Pyrexia
8 (.51%)
Swelling Face
8 (.51%)
Vaginal Erythema
8 (.51%)
Vaginal Infection
8 (.51%)
Vulval Oedema
8 (.51%)
Haematoma
7 (.44%)
Anaemia
6 (.38%)
Asthenopia
6 (.38%)
Drug Exposure During Pregnancy
6 (.38%)
Dry Mouth
6 (.38%)
Excoriation
6 (.38%)
Eye Movement Disorder
6 (.38%)
Haemorrhage Subcutaneous
6 (.38%)
Insomnia
6 (.38%)
Labia Enlarged
6 (.38%)
Mental Disorder
6 (.38%)
Metrorrhagia
6 (.38%)
Oedema Mouth
6 (.38%)
Pain In Extremity
6 (.38%)
Rash
6 (.38%)
Skin Exfoliation
6 (.38%)
Vulvovaginal Mycotic Infection
6 (.38%)
Abasia
5 (.32%)
Burning Sensation
5 (.32%)
Cleft Lip
5 (.32%)
Feeling Hot
5 (.32%)
Fungal Infection
5 (.32%)
Medication Error
5 (.32%)
Neural Tube Defect
5 (.32%)
Urticaria
5 (.32%)
Abdominal Distension
4 (.25%)
Asphyxia
4 (.25%)
Blindness Transient
4 (.25%)
Chest Pain
4 (.25%)
Deafness Transitory
4 (.25%)
Haemoglobin Decreased
4 (.25%)
Haemoptysis
4 (.25%)
Haemorrhage
4 (.25%)
Hyperacusis
4 (.25%)
Iron Deficiency Anaemia
4 (.25%)
Malaise
4 (.25%)
No Adverse Event
4 (.25%)
Pericardial Haemorrhage
4 (.25%)
Pharyngeal Oedema
4 (.25%)
Pulmonary Haemorrhage
4 (.25%)
Shock Haemorrhagic
4 (.25%)
Skin Irritation
4 (.25%)
Application Site Pain
3 (.19%)
Back Pain
3 (.19%)
Bladder Pain
3 (.19%)
Blood Pressure Decreased
3 (.19%)
Breast Swelling
3 (.19%)
Congenital Cardiovascular Anomaly
3 (.19%)
Cough
3 (.19%)
Epistaxis
3 (.19%)
Expired Drug Administered
3 (.19%)
Foetal Disorder
3 (.19%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Vagistat, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Vagistat is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Vagistat

What are the most common Vagistat adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Vagistat, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Vagistat is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Vagistat According to Those Reporting Adverse Events

Why are people taking Vagistat, according to those reporting adverse events to the FDA?

Vulvovaginal Mycotic Infection
347
Vaginal Mycosis
327
Fungal Infection
50
Genital Pruritus Female
46
Product Used For Unknown Indication
30
Oral Candidiasis
27
Show More Show More
Vaginal Burning Sensation
20
Tinea Pedis
15
Drug Use For Unknown Indication
13
Vaginal Infection
12
Vaginal Discharge
11
Rash
8
Vulvovaginal Pruritus
8
Vulvovaginal Candidiasis
7
Pruritus
6
Tinea Infection
5
Oral Fungal Infection
5
Hypothyroidism
5
Vulvovaginal Discomfort
4
Accidental Exposure
4
Tinea Cruris
4
Oesophageal Candidiasis
4
Onychomycosis
4
Genital Discharge
4
Stomatitis
3
Prophylaxis
3
Vulvovaginitis
3
Limb Discomfort
2
Vaginal Odour
2
Pulmonary Mycosis
2
Oropharyngitis Fungal
2
Bacterial Infection
2
Candidiasis
2
Oropharyngeal Candidiasis
2
Injury
1
Exposure During Breast Feeding
1
Tinea Capitis
1
Cheilitis
1
Maternal Exposure During Pregnancy
1
Drug Exposure Via Breast Milk
1
Chemical Poisoning
1
Malabsorption
1
Vitamin B1 Deficiency
1
Ill-defined Disorder
1
Aphthous Stomatitis
1
Antifungal Prophylaxis
1
Pain
1
Fungal Skin Infection
1
Cellulitis
1
Antifungal Treatment
1
Vulvitis
1

Vagistat Case Reports

What Vagistat safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Vagistat. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Vagistat.